Background: MOG-Abs distinguish a group of inflammatory disorders which can be preceded by specific or non-specific infections. Few single cases have been reported in association with SARS-CoV-2 infection, but a specific study on the correlation between COVID-19 and MOG-associated disorder (MOGAD) has not been performed, yet. Aim of this study is to determine the impact of the pandemic on this condition. Methods: We analysed SARS-CoV-2 serology in newly diagnosed MOG-Abs patients (August 1st 2020-May 31st 2021). MOG-Ab seronegative age and time-matched subjects were used as controls. SARS-CoV-2 IgG were analysed using an anti-SARS-CoV-2 FDA-approved ELISA assay (Euroimmun, Luebeck, Germany) and confirmed with a trimeric anti-SARS-CoV-2 S1/S2 IgG immunochemiluminescent test (DiaSorin), concomitantly assaying anti-Receptor Binding Domain (RBD) of spike protein (Beckman) IgG and anti-RBD total Ig (Roche). We then compared the number of cases referred in the last 3 years. Results: SARS-CoV-2 IgG were more common (12/30, 40%) in MOGAD than in controls (6/30, 20%), although the difference was not significant (p=0.16; OR=2.67, 95% CI 0.85-9.17). The most common clinical presentations of MOGAD SARS-CoV-2 seropositive cases included optic neuritis (n=6) and myelitis (n=3). The number of diagnosed cases increased in the last 3 years, in particular, when including cases referred before the COVID-19 pandemic, in the initial phase of the first wave and in the late phase of the second wave (n=9, rate 10.6% in 2019; n=13, rate 12.3% in 2020; n=and 15, rate 14.7% in 2021). Conclusion: Our findings provide preliminary data on SARS-CoV-2 as a potential trigger of MOGAD.

Is there a correlation between MOGAD and SARS-CoV-2 infection?

Mariotto, Sara
;
Carta, Sara;Dinoto, Alessandro;Lippi, Giuseppe;Salvagno, Gian Luca;Ferrari, Sergio
2022

Abstract

Background: MOG-Abs distinguish a group of inflammatory disorders which can be preceded by specific or non-specific infections. Few single cases have been reported in association with SARS-CoV-2 infection, but a specific study on the correlation between COVID-19 and MOG-associated disorder (MOGAD) has not been performed, yet. Aim of this study is to determine the impact of the pandemic on this condition. Methods: We analysed SARS-CoV-2 serology in newly diagnosed MOG-Abs patients (August 1st 2020-May 31st 2021). MOG-Ab seronegative age and time-matched subjects were used as controls. SARS-CoV-2 IgG were analysed using an anti-SARS-CoV-2 FDA-approved ELISA assay (Euroimmun, Luebeck, Germany) and confirmed with a trimeric anti-SARS-CoV-2 S1/S2 IgG immunochemiluminescent test (DiaSorin), concomitantly assaying anti-Receptor Binding Domain (RBD) of spike protein (Beckman) IgG and anti-RBD total Ig (Roche). We then compared the number of cases referred in the last 3 years. Results: SARS-CoV-2 IgG were more common (12/30, 40%) in MOGAD than in controls (6/30, 20%), although the difference was not significant (p=0.16; OR=2.67, 95% CI 0.85-9.17). The most common clinical presentations of MOGAD SARS-CoV-2 seropositive cases included optic neuritis (n=6) and myelitis (n=3). The number of diagnosed cases increased in the last 3 years, in particular, when including cases referred before the COVID-19 pandemic, in the initial phase of the first wave and in the late phase of the second wave (n=9, rate 10.6% in 2019; n=13, rate 12.3% in 2020; n=and 15, rate 14.7% in 2021). Conclusion: Our findings provide preliminary data on SARS-CoV-2 as a potential trigger of MOGAD.
COVID-19
MOG
SARS-CoV-2
myelitis
optic neuritis
File in questo prodotto:
File Dimensione Formato  
Euro J of Neurology - 2022 - Mariotto - Is there a correlation between MOG‐associated disorder and SARS‐CoV‐2 infection.pdf

accesso aperto

Descrizione: CC BY-NC-ND 4.0 publisher version
Tipologia: Versione dell'editore
Licenza: Creative commons
Dimensione 1.01 MB
Formato Adobe PDF
1.01 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/1058663
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 6
social impact